BeStock  
Stocks › Biotechnology › LBRX

LB Pharmaceuticals LBRX

US equityMarket cap rank #3009Biotechnology
$38.85 −$1.19 (-2.97%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $38.85 0.00%
Open$39.53
Prev close$40.04
Day range$38.57 – $40.67
Volume303.1K
Market cap$1.26B
P/E (TTM)38.3
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$62.50M-1,091.3% YoY
Net profit-$59.07M-1,561.0% YoY
Diluted EPS-$1.79-193.4% YoY
Free cash flow-$64.36M-1,808.2% YoY
Operating cash flow-$64.29M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-5.1MDec '24$-5.3MMar '25$-4.9MJun '25$-3.6MSep '25$-11.5MDec '25$-19.1MMar '26$-51.6MJun '26$-59.1MSep '26

Diluted EPS by quarter

-1.43Dec '24-0.24Mar '25-0.22Jun '25-0.61Sep '25-0.45Dec '25-0.67Mar '26-1.71Jun '26-1.79Sep '26

Free cash flow by quarter

$-5.9MDec '24$-8.1MMar '25$-5.6MJun '25$-3.4MSep '25$-18.1MDec '25$-23.3MMar '26$-38.0MJun '26$-64.4MSep '26

Annual revenue

$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-38.8%
Return on assets-36.5%
Return on invested capital-40.4%
Current ratio14.78
Liabilities / assets7.9%
Cash & investments$403.76M
Total debt$4.20M
Net cash (debt)$399.56M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $62.50M $53.92M $22.10M $30.40M $13.87M
Selling and Admin Expenses $10.98M $9.77M $7.46M $13.66M $5.39M
-General & Admin Expense $10.98M $9.77M $7.46M $13.66M $5.39M
Research & Development $51.52M $44.15M $14.65M $16.74M $8.48M
Operating Profit -$62.50M -$53.92M -$22.10M -$30.40M -$13.87M
Net Non-Operating Interest Income (Expense) $3.77M $2.97M $2.85M $3.92M $2.80M
Non-Operating Interest Income $3.77M $2.97M $2.85M $3.92M $2.80M
Other Income (Expense) -$339,000.00 -$662,000.00 $200,000.00 $1.28M -$401,000.00
Gain on Sale of Security -$339,000.00 -$662,000.00 $200,000.00 $1.28M -$401,000.00
Pretax Profit -$59.07M -$51.60M -$19.05M -$25.20M -$11.47M
Tax $0.00 $0.00 $0.00 $1,000.00 $1,000.00
Net Profit -$59.07M -$51.60M -$19.05M -$25.21M -$11.47M
Profit from Continuing Operations -$59.07M -$51.60M -$19.05M -$25.21M -$11.47M
Net Income to Parent Company -$59.07M -$51.60M -$19.05M -$25.21M -$11.47M
Net Income to Common Stockholders -$59.07M -$51.60M -$19.05M -$25.21M -$11.47M
Basic EPS -$1.79 -$1.71 -$0.67 -$3.13 -$0.45
Diluted EPS -$1.79 -$1.71 -$0.67 -$3.13 -$0.45

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $453.37M $361.69M $393.48M $312.93M $312.93M
Total Current Assets $447.12M $355.30M $389.07M $308.43M $308.43M
Cash and Cash Equivalents & Short-Term Investments $403.76M $327.79M $365.64M $295.21M $295.21M
-Cash and Cash Equivalents $215.08M $283.11M $320.68M $250.17M $250.17M
-Short Term Investments $188.69M $44.68M $44.96M $45.04M $45.04M
Prepaid Assets $38.69M $26.50M $22.65M $12.74M $12.74M
Other Current Assets $4.67M $1.01M $787,000.00 $478,000.00 $478,000.00
Total Non-Current Assets $6.25M $6.39M $4.41M $4.50M $4.50M
Net PPE $5.46M $5.61M $3.63M $3.73M $3.73M
-Gross PPE $6.18M $6.21M $4.13M $4.15M $4.15M
-Accumulated Depreciation -$723,000.00 -$599,000.00 -$502,000.00 -$420,000.00 -$420,000.00
Other Non-Current Assets $788,000.00 $782,000.00 $776,000.00 $770,000.00 $770,000.00
Total Liabilities $35.73M $29.35M $14.79M $11.62M $11.62M
Total Current Liabilities $30.25M $23.56M $10.91M $7.44M $7.44M
Payables $6.88M $3.49M $7.12M $2.13M $2.13M
-Accounts Payable $6.88M $3.49M $7.12M $2.13M $2.13M
Current Accrued Expenses $19.08M $16.43M $1.71M $2.39M $2.39M
Short-Term Debt and Capital Lease Obligation $956,000.00 $844,000.00 $730,000.00 $730,000.00 $730,000.00
-Current Capital Lease Obligation $956,000.00 $844,000.00 $730,000.00 $730,000.00 $730,000.00
Total Non-Current Liabilities $5.48M $5.78M $3.88M $4.18M $4.18M
Long Term Debt and Capital Lease Obligation $4.20M $4.37M $2.74M $2.84M $2.84M
-Long Term Capital Lease Obligation $4.20M $4.37M $2.74M $2.84M $2.84M
Derivative Product Liabilities $1.28M $1.41M $1.14M $1.34M $1.34M
Total Equity $417.64M $332.35M $378.69M $301.31M $301.31M
Stockholders' Equity $417.64M $332.35M $378.69M $301.31M $301.31M
Capital Stock $3,000.00 $3,000.00 $3,000.00 $3,000.00 $3,000.00
-Common Stock $3,000.00 $3,000.00 $3,000.00 $3,000.00 $3,000.00
Additional Paid-In Capital $677.43M $532.34M $527.06M $430.67M $430.67M
Retained Earnings -$259.25M -$200.19M -$148.58M -$129.53M -$129.53M
Gains/Losses Not Affecting Retained Earnings -$545,000.00 $186,000.00 $208,000.00 $168,000.00 $168,000.00
Convertible preferred securities – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$64.29M -$37.63M -$23.29M -$35.21M -$18.10M
Net cash flow from continuing operations -$64.29M -$37.63M -$23.29M -$35.21M -$18.10M
Net Income from Continuing Operations -$59.07M -$51.60M -$19.05M -$25.21M -$11.47M
Gain/Loss from Continuing Operations $339,000.00 $662,000.00 -$200,000.00 -$1.27M $409,000.00
Depreciation & Depletion & Amortization $124,000.00 $97,000.00 $82,000.00 $321,000.00 $85,000.00
Other Non-Cash Items $95,000.00 $93,000.00 $50,000.00 $147,000.00 $47,000.00
Change in Working Capital -$9.07M $8.29M -$6.75M -$13.65M -$9.53M
-Change in Receivables $237,000.00 -$123,000.00 $103,000.00 -$268,000.00 -$100,000.00
-Change in Prepaid Assets -$15.27M -$4.07M -$10.22M -$12.34M -$11.30M
-Change in Payables and Accrued Expense $6.02M $12.54M $3.46M -$910,000.00 $1.97M
-Change in Other Current Liabilities -$60,000.00 -$57,000.00 -$99,000.00 -$134,000.00 -$98,000.00
Net cash flow from investing -$144.65M $89,000.00 -$32,000.00 -$39.89M -$40,000.00
Net Cash Flow from Continuing Investing Activities -$144.65M $89,000.00 -$32,000.00 -$39.89M -$40,000.00
Net PPE Purchase and Sale -$70,000.00 -$363,000.00 -$32,000.00 -$52,000.00 -$40,000.00
Net Investment Purchase and Sale -$144.58M $452,000.00 $0.00 -$39.84M $0.00
Financing Cash Flow $140.92M -$19,000.00 $93.83M $302.56M -$1.17M
Net Cash Flow from Continuing Financing Activities $140.92M -$19,000.00 $93.83M $302.56M -$1.17M
Net Common Stock Issuance $150.00M $0.00 $100.00M $327.75M $0.00
Proceeds from Stock Option Exercised $42,000.00 $48,000.00 $29,000.00 $247,000.00 $0.00
Net Other Financing Charges -$9.13M -$67,000.00 -$6.20M -$25.44M -$1.17M
Ending Cash Balance $215.86M $283.89M $321.45M $250.94M $250.94M
Net Change in Cash -$68.03M -$37.56M $70.51M $227.47M -$19.31M
Beginning Cash Balance $283.89M $321.45M $250.94M $23.48M $270.26M
Free Cash Flow -$64.36M -$37.99M -$23.32M -$35.26M -$18.14M
Net Preferred Stock Issuance – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on LBRX.

Sign in to join the discussion.

Scroll to Top